(Press-News.org) A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans. Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. The research will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday).
Laboratory studies of the drug, MK-4827, have shown that it inhibits proteins called PARP1 and PARP2 (poly(ADP)-ribose polymerase). PARP is involved in a number of cellular processes and one of its important functions is to assist in the repair of single-strand breaks in DNA. If one single-strand broken DNA is replicated (replication occurs before cell division) then it results in a double-strand break. By inhibiting the action of PARP, double-strand breaks occur, leading to cell death. Tumours that are caused by a mutation in the BRCA1 or BRCA2 genes are susceptible to cell death through PARP inhibition because correctly functioning BRCA genes assist in repairing double-strand DNA breaks via a process called homologous-recombination-dependent DNA repair, whereas mutated versions are unable to perform this role. Normal cells don't replicate as often as cancer cells and they still have homologous repair operating; this enables them to survive the inhibition of PARP and makes PARP a good target for anti-cancer therapy.
In a Phase I trial conducted at the H Lee Moffitt Cancer Center (Tampa Florida, USA), University of Wisconsin-Madison (Madison, USA) and the Royal Marsden Hospital (London, UK), MK-4827 was given to 59 patients (46 women, 13 men) with a range of solid tumours such as non-small cell lung cancer (NSCLC), prostate cancer, sarcoma, melanoma and breast and ovarian cancers. Some patients had cancers caused by mutations in the BRCA1/2 genes, such as breast and ovarian cancer, but others had cancers that had arisen sporadically.
The drug was given in pill form once a day, and the researchers found that the maximum tolerated dose was 300 mg a day. Dr Robert Wenham, Clinical Director for Gynecologic Oncology in the Department of Women's Oncology at the Moffitt Cancer Center, who is presenting data on behalf of the participating investigators, said: "MK-4827 is generally well tolerated, with the main dose-limiting toxicity being thrombocytopenia – an abnormal decrease in the number of platelets in the circulatory blood. The most common side effects are mild nausea, vomiting, anorexia and fatigue."
The researchers saw anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Ten patients with breast and ovarian cancers had partial responses, with progression-free survival between 51-445 days, and seven of these patients are still responding to treatment. Four patients (two with ovarian cancer and two with NSCLC) had stable disease for between 130-353 days.
Dr Wenham said: "Most patients in the trial had exhausted standard therapies and those who responded to this drug have benefited. Several patients have been receiving treatment for more than a year. The responses mean that MK-4827 is working as hoped and justify additional studies. Just how well MK-4827 works compared to other treatments is the goal of the next set of studies."
He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA genes. This may explain why responses have been reported for this class of drugs in non-BRCA mutant cancers."
Dr Wenham and his colleagues are recruiting more patients for additional studies and an expansion of the existing trial. "We want to understand what types of cancers will respond best to treatment with MK-4827," he said. "Cohorts are currently open for patients with ovarian cancer patients without germ-line BRCA mutations, and prostate cancer patients. Cohorts will open soon for patients with T-cell prolymphocytic leukaemia, endometrial cancer, breast cancer and colorectal cancer. MK-4827 is also being studied in combination with conventional chemotherapy drugs."
###
Abstract no: 362. Poster on Thursday 18 November in the Exhibition Hall (ground level) from 08.00/09.00 hrs to 18.00 hrs CET.
NB: due to unforeseen circumstances, Dr Robert Wenham is unable to attend the Symposium. His co-author Dr Shahneen Sandhu will attend the poster session in his place.
Notes:
[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].
[2] This study was funded by Merck & Co. Inc. MK-4827 is owned by Merck & Co. Inc.
WHAT:
In a review article appearing in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine research under way to address the limitations of currently available influenza vaccines and develop more efficient and reliable strategies to make vaccines to protect against seasonal as well as pandemic influenza. Although licensed seasonal flu vaccines safely and effectively protect most people who receive them from illness and death, the degree of protection varies ...
Scientists at Emory University and the University of St. Andrews have solved the structure of a key protein from Lassa virus, which is endemic to West Africa and can cause a deadly hemorrhagic fever.
The structure reveals how the virus evades its host's immune system, and how it hijacks infected cells' vital machinery in a process scientists call "cap-stealing." Details of the structure could guide future efforts at antiviral drug discovery and vaccine development.
The results are published in this week's issue of Nature.
Lassa virus represents a family of viruses ...
GOLDEN, Colo. (November 17, 2010) – HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants. This information is available, free to the public, at HealthGrades.com and is intended ...
PHILADELPHIA – A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded – for the first time – that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.
Stats and Treatment
Prostate cancer remains the most common non-skin cancer and the second leading cause of cancer death in men in the United States. In fact, about 218,000 ...
A new study found that patients with osteoarthritis (OA) of the knee who also have pain in other joints were more likely to experience greater knee pain. Specifically, pain in the lower back as well as foot pain and elbow pain on the same side as the affected knee were associated with more severe knee pain. Full details appear in the December issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.
Knee OA is the leading cause of disability in the U.S., with nearly 4.3 million adults over age 60 having ...
VIDEO:
Cells from a pig's cardiovascular system with different components are labeled simultaneously, using the new Multi-Label technology.
Click here for more information.
The cells in the different parts of this video are always the same, but, like actors using make-up to highlight different facial features, they have fluorescent labels that mark different cellular components in different colours: blue shows the nucleus, yellow shows tubulin (a component of the cell's scaffolding), ...
Ninety-six per cent of patients with back problems were satisfied with the assessment carried out by a specially trained nurse practitioner, according to a study in the December issue of the Journal of Advanced Nursing.
Seventy-four per cent were happy to see her rather than wait up to a year to see a surgeon, with less than a quarter of those who preferred to see a surgeon saying that the extra wait was acceptable.
The pilot study at Toronto Western Hospital in Ontario, Canada, was judged a resounding success after nurse practitioner Angela Sarro came up with exactly ...
Researchers have trapped and held the atoms, the anti-matter counterpart of hydrogen, using an experiment called ALPHA at CERN in Switzerland. Anti-matter particles are instantly annihilated when they come into contact with matter and, until now, it has not been possible to study anti-hydrogen in any detail. The experiment has brought scientists closer to understanding the structure and composition of anti-matter.
The ALPHA experiment was developed to cool and slow down the anti-particles that make up anti-hydrogen and mix them to produce antihydrogen. Some of the ...
Social factors can play a key role in whether or not a child is diagnosed as autistic, a new study has found.
Boys were more likely to receive a diagnosis of autistic spectrum disorder (ASD) than girls, even when symptoms were equally severe, according to researchers at the universities of Exeter and Bristol.
"We wanted to find out what distinguishes those children without diagnosis but with autistic traits from those who have received a formal ASD diagnosis in the clinic," explained lead researcher Ginny Russell, from Egenis at the University of Exeter. "We thought ...
Scientists at the University of Cambridge are working on ways to improve the efficiency of the ammonia synthesis process. With between 3-5% of the world's natural gas used to create artificial fertilizers, the new research could have major implications for both the agricultural and energy sectors.
Ammonia (NH3) is one of the most important chemicals in the modern world, due mainly to its use in the manufacture of artificial fertilisers. Ammonia synthesis (via the "Haber" or "Haber-Bosch" process) is vital to the production of 100 million tons of fertiliser per year, ...
